Annovis CEO to Present Multi-Protein Alzheimer’s Model, Phase 3 Buntanetap Data on May 13
Annovis Bio CEO Maria Maccecchini will present on May 13, 2026 at Fierce Biotech Week, outlining a multi-protein Alzheimer’s disease model involving amyloid, tau, alpha-synuclein and TDP-43. She will emphasize Phase 3 oral therapy buntanetap’s mechanism reducing multiple neurotoxic proteins and cite encouraging biomarker results from ongoing trials.
1. Presentation Overview
Maria Maccecchini, Ph.D., President and CEO of Annovis Bio, will deliver a 25-minute presentation titled “The Multi-Protein Reality of Alzheimer’s Disease” at Fierce Biotech Week 2026 on May 13 at 1:40 PM in Picasso 4&5. The talk will be followed by a Q&A session open to conference participants.
2. Scientific Rationale
Maccecchini will trace decades of research linking amyloid, tau, alpha-synuclein and TDP-43 aggregation in Alzheimer’s progression, challenging the field’s single-protein focus. The presentation will argue for a holistic therapeutic approach targeting all major neurotoxic proteins.
3. Phase 3 Trial Status
Annovis’s lead oral candidate, buntanetap, is in a pivotal Phase 3 clinical trial designed to reduce expression of multiple aggregating proteins. The drug has shown meaningful clinical benefits and encouraging biomarker improvements in earlier phases, supporting its translational inhibitor mechanism.